Charles River Laboratories
CRL
$202.10
+8.31%
Charles River Laboratories International, Inc. is a leading global provider of essential products and services for drug discovery and development, operating within the Medical - Diagnostics & Research industry. The company is a market leader in preclinical research, distinct for its integrated portfolio spanning research models, discovery services, safety assessment, and manufacturing support, which positions it as a critical partner for biopharmaceutical clients. The current investor narrative centers on navigating a challenging post-pandemic demand normalization, with recent quarterly results showing revenue contraction and a significant net loss, raising questions about the timing of a recovery in biotech R&D spending and the company's ability to manage costs and restore profitability.…
CRL
Charles River Laboratories
$202.10
Investment Opinion: Should I buy CRL Today?
Rating: Hold. The core thesis is that CRL presents a high-risk, high-potential-reward turnaround story where severe fundamental deterioration is balanced by deeply depressed valuation and strong underlying cash generation, but the timing of a recovery remains too uncertain to warrant a Buy rating.
Supporting evidence includes a historically low Price-to-Sales ratio of 2.51x, robust TTM free cash flow of $518.5 million providing financial flexibility, a forward P/E of 15.03x that prices in subdued growth, and a recent 21.37% one-month price rebound suggesting some near-term capitulation may be over. However, these positives are counterbalanced by the Q4 revenue decline of -0.83% YoY and a catastrophic net margin of -27.8%.
The thesis would upgrade to a Buy on clear signs of fundamental stabilization: specifically, a return to sequential revenue growth and a restoration of positive net income. It would downgrade to a Sell on a breakdown below the 52-week low of $144.26 or another quarter of significant net losses. Relative to its own history, the stock appears undervalued on a sales basis, but it is fairly valued to slightly overvalued on an earnings basis given the current lack of profitability, implying the market expects a eventual but delayed recovery.
Sign up to view all
CRL 12-Month Price Forecast
CRL is in a transitional phase where bearish fundamentals conflict with bullish valuation and cash flow signals. The base case of a slow, volatile recovery is most probable, but the high beta means news-driven swings will be significant. The stance is neutral due to the high degree of binary uncertainty around the biotech spending cycle. An upgrade to bullish would require concrete evidence of margin recovery and sustained order book strength in the next two quarters. A downgrade to bearish would be triggered by a failure to return to profitability or a breakdown of key technical support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Charles River Laboratories's 12-month outlook, with a consensus price target around $262.73 and implied upside of +30.0% versus the current price.
Average Target
$262.73
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$162 - $263
Analyst target range
Analyst coverage appears limited with only 5 analysts providing estimates, indicating this may be a less-followed mid-cap name which can lead to higher volatility. The available data shows consensus estimates for EPS and revenue but does not provide a consensus price target, Buy/Hold/Sell distribution, or target price range, making a quantitative sentiment assessment impossible. Given the insufficient explicit target data, the implication is that investor conviction is likely lower and price discovery may be less efficient, placing greater emphasis on monitoring the company's execution against its own guidance and the broader biotech R&D spending recovery for directional cues.
Bulls vs Bears: CRL Investment Factors
The investment debate for CRL is a classic battle between deep value and deteriorating fundamentals. The bear case currently holds stronger evidence, anchored by the severe Q4 net loss of -$276.6 million and a clear multi-quarter revenue deceleration. The most critical tension is the timing and magnitude of a recovery in biotech R&D spending. If spending rebounds, the stock's historically low PS ratio of 2.51x and strong free cash flow could fuel a powerful re-rating. If the downturn persists or deepens, the company's high operating leverage and elevated beta could lead to further significant downside from the current price.
Bullish
- Strong Free Cash Flow Generation: Despite recent earnings volatility, CRL generated $518.5 million in TTM free cash flow, providing significant financial resilience and internal funding flexibility. This robust cash flow yield supports the company's ability to navigate a downturn and invest for recovery.
- Valuation at Historical Lows: The stock's Price-to-Sales (PS) ratio of 2.51x is near the bottom of its recent historical range, having peaked at 10.08x in Q4 2025. This substantial compression suggests the market has priced in significant pessimism, creating a potential value opportunity if fundamentals stabilize.
- Recent Sharp Price Rebound: The stock is up 21.37% over the past month, indicating a potential oversold bounce and a shift in near-term momentum. This recovery from the 52-week low of $144.26 suggests some investors are betting on a cyclical turnaround in biotech R&D spending.
- Critical Market Position: As a leading global provider of essential preclinical research services, CRL holds a critical, integrated position in the drug development supply chain. This structural role provides a degree of business model resilience despite cyclical demand headwinds.
Bearish
- Severe Profitability Deterioration: Q4 2025 results showed a catastrophic net loss of -$276.6 million (net margin of -27.8%), a sharp reversal from Q3's $54.4 million profit. This collapse, alongside gross margin compression from 33.72% to 30.96%, indicates severe operational and potential one-time cost issues.
- Revenue Contraction & Deceleration: Q4 2025 revenue declined 0.83% YoY to $994.2 million, continuing a sequential deceleration from Q3's $1.00B and Q2's $1.03B. This trend confirms the negative impact of post-pandemic demand normalization and a softer biotech funding environment on top-line growth.
- High Volatility & Underperformance: With a beta of 1.449, CRL is 45% more volatile than the market, amplifying downside risk. The stock has underperformed the S&P 500 by 15.84% over the past six months, reflecting weak investor confidence and a challenging fundamental backdrop.
- Limited Analyst Coverage & Sentiment: Only 5 analysts provide estimates, and no consensus price target is available, indicating lower institutional conviction and potentially less efficient price discovery. This lack of clear directional guidance from the sell-side increases uncertainty for investors.
CRL Technical Analysis
The stock is in a pronounced downtrend, having declined 6.12% over the past six months and 8.61% year-to-date, significantly underperforming the broader market. With a current price of $185 (as of the last close in the data), it is trading approximately 19% below its 52-week high of $228.88 and 28% above its 52-week low of $144.26, indicating it is positioned in the lower-middle portion of its annual range, suggesting potential value but within a context of sustained weakness. Recent momentum shows a sharp, volatile recovery attempt, with the stock up 21.37% over the past month and 20.44% over three months, a stark reversal from the longer-term downtrend that suggests a possible oversold bounce or short-term mean reversion, though the high beta of 1.449 indicates this move is amplified and inherently more volatile than the market. Key technical support is anchored at the 52-week low of $144.26, while resistance sits near the 52-week high of $228.88; a sustained breakout above the recent recovery highs would be needed to signal a trend change, while a breakdown below support would confirm the primary downtrend's continuation, with the elevated beta underscoring the stock's higher risk profile for position sizing.
Beta
1.45
1.45x market volatility
Max Drawdown
-33.9%
Largest decline past year
52-Week Range
$144-$229
Price range past year
Annual Return
+36.2%
Cumulative gain past year
| Period | CRL Return | S&P 500 |
|---|---|---|
| 1m | +26.1% | -1.7% |
| 3m | +22.4% | +13.7% |
| 6m | -0.8% | +6.2% |
| 1y | +36.2% | +20.8% |
| ytd | -0.2% | +7.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRL Fundamental Analysis
Revenue growth has stalled and turned negative, with the most recent Q4 2025 revenue of $994.2 million representing a 0.83% year-over-year decline, and the sequential trend from Q3's $1.00 billion and Q2's $1.03 billion indicates a multi-quarter deceleration; the Discovery and Safety Assessment segment, at $591.6 million, remains the largest revenue driver, but overall top-line pressure reflects a softer biotech funding environment. Profitability has deteriorated sharply, with the company reporting a significant net loss of -$276.6 million in Q4 2025 (net margin of -27.8%), a stark contrast to the net income of $54.4 million in Q3 2025, while the gross margin of 30.96% in Q4 also compressed from 33.72% in the prior quarter, highlighting severe margin pressure and potential one-time charges impacting the bottom line. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.97, and while the current ratio of 1.29 indicates adequate short-term liquidity, the key positive is robust free cash flow generation, with TTM free cash flow of $518.5 million providing internal funding flexibility and a cash flow yield that offers a measure of financial resilience despite the earnings volatility.
Quarterly Revenue
$994227000.0B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.30%
Latest Quarter
Free Cash Flow
$518494000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRL Overvalued?
Given the negative net income and EPS of -$0.014, the primary valuation metric is the Price-to-Sales (PS) ratio. The trailing PS ratio is 2.51x, and while a forward PE of 15.03x is available, the sales multiple is more relevant for the current unprofitable phase. Compared to industry averages, specific sector multiples are not provided in the data, but the stock's EV/Sales of 2.94x can be assessed contextually; the valuation appears subdued relative to historical norms, potentially reflecting the earnings disappointment. Historically, the stock's own PS ratio has fluctuated significantly, reaching as high as 10.08x in Q4 2025 and averaging much higher levels in prior years; the current PS of 2.51x sits near the bottom of its recent historical range, suggesting the market has priced in substantial pessimism regarding growth and margin recovery, which could represent a value opportunity if fundamentals stabilize.
PE
-70.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -11x~77x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
31.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute, centered on severe margin pressure and earnings volatility. The Q4 2025 net loss of -$276.6 million and gross margin compression to 30.96% from 33.72% the prior quarter highlight significant cost management challenges, potentially including large one-time charges. While the debt-to-equity ratio of 0.97 is moderate and TTM free cash flow of $518.5 million provides a buffer, the company remains dependent on a recovery in biotech client spending to restore profitability, with revenue already contracting 0.83% YoY.
Market & Competitive Risks are elevated due to CRL's high sensitivity to the biotech funding cycle and its premium valuation on certain metrics. The stock's beta of 1.449 indicates it will be disproportionately impacted by broader market downturns. Furthermore, the forward P/E of 15.03x and EV/EBITDA of 31.51x, while not extreme, could compress further if growth fails to materialize, especially given the sector's exposure to potential regulatory headwinds or a prolonged period of high interest rates suppressing biotech R&D budgets.
Worst-Case Scenario involves a prolonged recession in biotech venture capital funding, leading to sustained project cancellations and pricing pressure. This could trigger further sequential revenue declines, preventing margin recovery and leading to consecutive quarterly losses. In this adverse scenario, the stock could realistically retest its 52-week low of $144.26, representing a downside of approximately -22% from the current price of $185. A breach of this support could lead to a maximum drawdown approaching the historical -33.88% level, potentially driven by a loss of investor confidence in the recovery timeline.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Continued earnings volatility and margin pressure, as evidenced by the Q4 net margin of -27.8%. 2) Market/Cyclical Risk: Prolonged weakness in biotech R&D spending, upon which CRL's revenue is directly dependent. 3) Volatility Risk: The stock's high beta of 1.449 leads to amplified price swings versus the market. 4) Sentiment Risk: Limited analyst coverage (only 5 analysts) can lead to lower liquidity and less efficient price discovery during periods of stress.
The 12-month forecast is highly scenario-dependent. The base case (55% probability) sees a slow recovery with a target range of $185-$210, implying the stock trades around current levels. The bull case (25% probability), driven by a sharp biotech spending rebound, targets $228-$250. The bear case (20% probability), where the downturn deepens, targets a retest of the 52-week low in the $144-$165 range. The base case is most likely, predicated on the assumption that profitability gradually improves but revenue growth remains subdued.
CRL's valuation is mixed, presenting a dichotomy. On a sales basis, it appears deeply undervalued with a PS ratio of 2.51x, down sharply from a peak of 10.08x, suggesting the market has priced in extreme pessimism. On an earnings basis, with a trailing P/E of -69.93 due to recent losses, valuation is not meaningful. The forward P/E of 15.03x implies the market expects a return to modest profitability. Overall, the stock is undervalued relative to its own history but fairly valued relative to the current challenged growth profile, implying the market expects a slow recovery.
CRL is a high-risk, high-potential-reward stock that is not a good buy for conservative investors. For aggressive investors with a multi-year horizon, the current Price-to-Sales ratio of 2.51x (near historical lows) and strong $518.5M free cash flow present a compelling value case if a biotech recovery materializes. However, the severe Q4 net loss of -$276.6M and revenue contraction indicate significant near-term fundamental risk. It could be a good buy for those who can tolerate volatility and are confident in a 2027 biotech spending rebound.
CRL is unsuitable for short-term trading due to its high beta (1.449) and current lack of positive earnings catalysts, which could lead to unpredictable volatility. It is better suited for a long-term (3+ year) investment horizon, allowing time for the biotech funding cycle to potentially turn and for the company's cost actions and integrated model to restore profitability. The lack of a dividend also removes an income component, making total return dependent entirely on capital appreciation from a successful turnaround.